Printer Friendly

SANOFI WINTHROP AND RHONE-POULENC RORER INC. SIGN MARKETING, DISTRIBUTION AGREEMENT FOR ANTI-ANGINAL

 SANOFI WINTHROP AND RHONE-POULENC RORER INC. SIGN MARKETING,
 DISTRIBUTION AGREEMENT FOR ANTI-ANGINAL


STERLING WINTHROP'S U.S. PHARMACEUTICAL UNIT, SANOFI WINTHROP, TO MARKET NITRONG EXTENDED-RELEASE ORAL NITRATE TABLETS FOR PREVENTION OF ANGINA
 NEW YORK and COLLEGEVILLE, Pa., July 8 /PRNewswire/ -- Sterling Winthrop Inc. and Rhone-Poulenc Rorer Inc. (NYSE: RPR) announced today that Sanofi Winthrop Pharmaceuticals, the U.S. marketing unit of Sterling Winthrop, Inc., will market NITRONG(R) (nitroglycerin) Extended-release oral tablets in the United States for the prevention of angina. NITRONG oral tablets provide a controlled-release formulation that is distinct among all oral nitrates.
 Sanofi Winthrop entered into an exclusive marketing and distribution agreement with a unit of Rhone-Poulenc Rorer Inc. to market NITRONG Extended-release oral tablets in the United States, its territories and possessions. The agreement will expire at the end of 1997 at which time Sanofi Winthrop and RPR can extend the agreement or enter into a co- promotion arrangement.
 "Given RPR's commitment to building our cardiovascular franchise in the U.S. and our current concentration of resources on marketing our anti-hypertensive calcium channel blocker Dilacor XR(R), this partnership with Sanofi Winthrop will ensure that appropriate resources are allocated to marketing and distributing NITRONG oral tablets in the U.S.," said Pierre Lapalme, RPR's senior vice president, North American Ethicals. Harry Shoff, president of Sanofi Winthrop Pharmaceuticals in the United States added, "The licensing of the NITRONG product allows Sanofi Winthrop to leverage our cardiovascular sales, marketing and medical experience to this unique product for the prevention of angina."
 NITRONG Extended-release oral tablets have been proven to significantly reduce the frequency and severity of angina attacks (NOTE 1). Moreover, NITRONG oral tablets have been shown to maintain effectiveness in treadmill exercise testing over prolonged periods of time, which is a proven test of efficacy for a nitrate (NOTES 1,2). These results signify that at the dosage schedules recommended, NITRONG oral tablets deliver an excellent profile of efficacy for the angina patient. Headaches and light headedness on standing sometimes accompany treatment with nitroglycerin.
 NITRONG oral tablets provide the physician and patient a recognized and affordable alternative to current angina therapies and is available in extended-release tablets of 2.6 mg and 6.5 mg strengths. NITRONG oral tablets are dosed three times a day in a regimen that can be tailored to the individual patient's needs, which should include a nitrate-free interval to avoid development of nitrate tolerance.
 Rhone-Poulenc Rorer Inc. is a global pharmaceutical company dedicated to the discovery, development, manufacture and marketing of human pharmaceuticals. The company reported annual revenues of $3.8 billion in 1991 and will spend over $500 million in research and development in 1992.
 Sanofi Winthrop Pharmaceuticals is the U.S. marketing unit of Sterling Winthrop Inc., a worldwide developer, manufacturer and marketer of pharmaceuticals and consumer health products.
 REFERENCES:
 1. Winsor T, Berger HJ. Oral nitroglycerin as a prophylactic antianginal drug: clinical, physiologic, and statistical evidence of efficacy based on a three-phase experimental design. "Am Heart J." 1975;90:611-626.
 2. Jorgensen E, Arvill A, Anggard E. Nitrate tolerance measured by exercise tests: a comparison between isosorbide-5-mononitrate and nitroglycerin in long-acting form. "Lakartidningen" 1991;88:1962-1968.
 -0- 7/8/92
 /CONTACT: David M. Marcou of Sterling Winthrop, 212-907-2672, Jane Green of Rhone-Poulenc Rorer, 215-454-3871/
 (RPR) CO: Sterling Winthrop Inc.; Rhone-Poulenc Rorer Inc. ST: New York, Pennsylvania IN: MTC SU: TNM


TM-SH -- NY056 -- 7583 07/08/92 16:53 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 8, 1992
Words:569
Previous Article:NATIONAL FOOD PROCESSORS ASSOCIATION SUPPORTS USDA POULTRY IRRADIATION PROPOSAL
Next Article:BENEFICIAL CORP. $3 BILLION SHELF DEBT RATED 'A+/A' BY FITCH -- FITCH FINANCIAL WIRE --
Topics:


Related Articles
WARNER-LAMBERT, RHONE-POULENC RORER AGREE TO CO-DEVELOP AND CO-PROMOTE ADVANCED QUINOLONE ANTIBACTERIAL IN U.S. AND CANADA
RHONE-POULENC RORER AND CHUGAI TO CO-DEVELOP, CO-MARKET TAXOTERE(R) FOR JAPAN
RHONE-POULENC RORER AND BOLAR RESTRUCTURE AGREEMENT ON DILTIAZEM IMMEDIATE AND SUSTAINED RELEASE FORMULATIONS
RHONE-POULENC RORER AND NOVEN PHARMACEUTICALS SIGN LICENSING AGREEMENT FOR TRANSDERMAL HORMONE REPLACEMENT THERAPY PRODUCTS
COMPUMED AND RHONE-POULENC RORER SIGN AGREEMENT TO PROMOTE BONE MINERAL DENSITY TESTS
RHONE-POULENC RORER AND FISONS ANNOUNCE AGREEMENT IN PRINCIPLE TO CO-PROMOTE TILADE(R) AND AZMACORT(R)
RHONE-POULENC RORER AND FISONS ANNOUNCE AGREEMENT IN PRINCIPLE TO CO-PROMOTE TILADE(R) AND AZMACORT(R)
RHONE-POULENC RORER AND FISONS ANNOUNCE AGREEMENT IN PRINCIPLE TO CO-PROMOTE TILADE(R) AND AZMACORT(R)
THE IMMUNE RESPONSE CORPORATION REGAINS ALL RIGHTS TO HIV IMMUNOTHERAPEUTIC FROM RHONE-POULENC RORER INC.
Rhone-Poulenc Rorer Inc. to Evaluate NanoSystems Drug Delivery Technology For Asthma

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters